Tests cholesterol-lowering drugs in adults with type 1 diabetes
Tests cholesterol-lowering medicines in adults with type 1 diabetes, observing effects on blood vessels.
Plain-language title generated from the registry record
Registry title: Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Key facts
- Where
- New York, United StatesSee the 4 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Source: NCT05641753, who can take part
Where in United States
- Mount Sinai School of MedicineNew York, United StatesTaking people
- New York VA HospitalNew York, United StatesTaking people
- NYC Health + Hospitals / BellevueNew York, United StatesTaking people
- NYU Langone HealthNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT05641753
- Record updated
- 28 October 2026
- Original description
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question.Read full original descriptionShow less
CHORD1 - CHOlesterol Lowering and Residual Risk in Diabetes, Type 1
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question.
This study will recruit 125 participants with Type 1 Diabetes (T1D) to:
1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal 2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and 3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.
Inclusion: Participants with previous diagnosis of T1D (as defined by American Diabetes Association or judgment of physician for at least 1 year); American Diabetes Association Criteria for diagnosis of diabetes (Must meet at least 1 of the following criteria):; i. FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 hours, OR; ii. 2-h PG ≥200 mg/dL (11.1 mmol/L) during OGTT. The test should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water, OR; iii. A1C ≥6.5% (48 mmol/mol), OR; iv. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L), AND; History of T1D (due to autoimmune β-cell destruction, usually leading to absolute insulin deficiency, including latent autoimmune diabetes of adulthood). Autoimmune markers include islet cell autoantibodies and autoantibodies to GAD (glutamic acid decarboxylase, GAD65), insulin, the tyrosine phosphatases islet antigen 2 (IA-2) and IA-2β, and zinc transporter 8, OR; Diagnosis of T1D and confirmed by review of records by 2 separate clinical members of the study team; Age ≥ 18 \& < 90; LDL-C >100mg/dl; Able and willing to provide written informed consent for the study.
Exclusion: Use of a PCSK9 inhibitor; Use of immunosuppressive therapy; Use of any antithrombotic therapy; Established cardiovascular disease on antithrombotic therapy; Recent infection in the past 30 days; A history of hemorrhagic diathesis; Chronic kidney disease (CrCl < 30ml/min); T2D, monogenic diabetes syndromes, or diabetes in the context of disease of the exocrine pancreas (such as pancreatitis, trauma or pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis); Anemia (hemoglobin < 9 g/dl) or thrombocytopenia (platelet count <75), or thrombocytosis (platelet count >600); Triglycerides >400mg/dl; Any hospitalization in the past 30 days; Use of aspirin; Use of NSAID within the past 72 hours; Pregnancy.